Compare Danaos Corporation (DAC) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaos Corporation vs Merck & Co., Inc. — how do they compare? Danaos Corporation trades at $128.26 (market cap $2.36B), while Merck & Co., Inc. trades at $123.51 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 126.4× Danaos Corporation's market cap, and Merck & Co., Inc. pays the higher dividend (2.82%). Which is the better fit depends on your goals.
| DAC | MRK | |
|---|---|---|
Market Cap | $2.36B | $298.31B |
Sector | Technology | Health |
52-Week High | $134.63 | $129.52 |
52-Week Low | $84.05 | $77.60 |
Enterprise Value | $2.36B | $341.72B |
Dividend Yield | 2.78% | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaos Corporation (DAC) trades at $129.35, up 0.75% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 4.57, P/B of 0.6, and net income margin of 49.85% (2026 trend). Recent Q1 2026 earnings beat expectations, and the company maintains a consistent dividend policy. Analyst sentiment is mixed with a 40% buy rating. The stock is near resistance at $130, with RSI_6 indicating potential overbought conditions.
The outlook for DAC remains positive due to attractive valuation, high profitability, and a robust containership backlog. Key risks include exposure to shipping rate volatility and capital allocation decisions. Upside potential is supported by earnings momentum and dividend yield, but investors should monitor industry cyclicality and execution on fleet expansion.
Merck (MRK) trades at $123.485, down 0.44% on the day, with a bullish technical signal and strong institutional accumulation. The company reported solid earnings beats in recent quarters despite a Q1 2026 loss, maintains robust profitability with a 73.91% gross margin and 13.59% net margin, and is actively expanding its oncology pipeline through acquisitions like Terns Pharmaceuticals. Cash flow from operations remains healthy at $16.47B for 2025, supporting strategic investments and shareholder returns.
Outlook remains positive with a $137.30 consensus price target representing 11% upside, supported by 67.57% analyst buy ratings. Key opportunities include pipeline expansion via M&A and sustained profitability, while risks involve integration of acquisitions, patent pressures, and competitive threats in oncology. The stock's valuation at 34.02 P/E appears elevated but justified by growth prospects and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
